The FDA is considering changes to the way it evaluates cardiovascular risks of medicines as more treatments for diabetes and other chronic conditions are linked to heart events, said Dr. John Jenkins, director of the agency's Office of New Drugs. An FDA panel recommended in July that the agency require companies to run long-term tests on the risk of heart problems tied to their products.

Full Story:

Related Summaries